

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

PrNORTRIPTYLINE

Nortriptyline Hydrochloride Capsules

Capsules, 10 mg and 25 mg nortriptyline (as nortriptyline hydrochloride), Oral

USP

Antidepressant

APOTEX INC.
150 Signet Drive
Toronto, Ontario
M9L 1T9

Date of Initial Authorization:
APR 06, 2021

Date of Revision:
NOV 29, 2024

Submission Control Number: 287666

RECENT MAJOR LABEL CHANGES

7 WARNINGS AND PRECAUTIONS, Cardiovascular	01/2024
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism	11/2024
7 WARNINGS AND PRECAUTIONS, Gastrointestinal	11/2024
7 WARNINGS AND PRECAUTIONS, General	11/2024
7 WARNINGS AND PRECAUTIONS, Hematologic	11/2024
7 WARNINGS AND PRECAUTIONS, Musculoskeletal	11/2024
7 WARNINGS AND PRECAUTIONS, Ophthalmologic	11/2024
7 WARNINGS AND PRECAUTIONS, Peri-Operative Considerations	11/2024
7 WARNINGS AND PRECAUTIONS, Renal	11/2024
7 WARNINGS AND PRECAUTIONS, Skin	11/2024
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women	11/2024

TABLE OF CONTENTS

Sections or subsections that are not applicable at the time of authorization are not listed.

RECENT MAJOR LABEL CHANGES	2
TABLE OF CONTENTS	2
PART I: HEALTH PROFESSIONAL INFORMATION	5
1 INDICATION	5
1.1 Pediatrics	5
1.2 Geriatrics	5
2 CONTRAINDICATIONS	5
3 SERIOUS WARNINGS AND PRECAUTIONS BOX	5
4 DOSAGE AND ADMINISTRATION	6
4.1 Dosing Considerations	6
4.2 Recommended Dose and Dosage Adjustment	6
4.2.1 Discontinuing Treatment.....	7
4.4 Administration.....	7
4.5 Missed Dose	7
5 OVERDOSAGE	7
6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING	9
7 WARNINGS AND PRECAUTIONS	9
7.1 Special Populations.....	14
7.1.1 Pregnant Women	14

7.1.2	Breast-feeding	15
7.1.3	Pediatrics	15
7.1.4	Geriatrics	15
8	ADVERSE REACTIONS	15
8.1	Adverse Reaction Overview.....	15
8.2	Clinical Trial Adverse Reactions	15
8.3	Less Common Clinical Trial Adverse Reactions	15
8.4	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data.....	16
8.5	Post-Market Adverse Reactions	16
9	DRUG INTERACTIONS	17
9.1	Serious Drug Interactions	17
9.2	Drug Interactions Overview.....	17
9.3	Drug-Behavioural Interactions.....	18
9.4	Drug-Drug Interactions.....	18
9.5	Drug-Food Interactions.....	26
9.6	Drug-Herb Interactions.....	26
9.7	Drug-Laboratory Test Interactions.....	26
10	CLINICAL PHARMACOLOGY	26
10.1	Mechanism of Action	26
10.2	Pharmacodynamics.....	27
10.3	Pharmacokinetics.....	27
11	STORAGE, STABILITY AND DISPOSAL	28
12	SPECIAL HANDLING INSTRUCTIONS.....	28
PART II: SCIENTIFIC INFORMATION		29
13	PHARMACEUTICAL INFORMATION.....	29
14	CLINICAL TRIALS	29
14.1	Clinical Trials by Indication.....	29
14.2	Comparative Bioavailability Studies.....	29
15	MICROBIOLOGY	30
16	NON-CLINICAL TOXICOLOGY	30

17 SUPPORTING PRODUCT MONOGRAPHS..... 30
PATIENT MEDICATION INFORMATION..... 31

PART I: HEALTH PROFESSIONAL INFORMATION

1 INDICATION

NORTRIPTYLINE (nortriptyline hydrochloride) is indicated for the relief of symptoms of depression. Endogenous depressions are more likely to be alleviated than are other depressive states.

1.1 Pediatrics

Pediatrics (< 18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NORTRIPTYLINE in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use (see [4.2 Recommended Dose and Dosage Adjustment](#); [7.1.3 Pediatrics](#)).

1.2 Geriatrics

Evidence from clinical studies and experience suggests that use in the geriatric population is associated with differences in safety or effectiveness (see [4.2 Recommended Dose and Dosage Adjustment](#); [7.1.4 Geriatrics](#)).

2 CONTRAINDICATIONS

NORTRIPTYLINE is contraindicated:

- in patients with hypersensitivity to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING](#). Cross-sensitivity between nortriptyline and other dibenzazepines is a possibility.
- in conjunction with, or within 14 days before or after treatment with a monoamine oxidase (MAO) inhibitor as it can increase the risk of serotonin toxicity (see [7 WARNINGS AND PRECAUTIONS, Neurologic](#); [9.1 Serious Drug Interactions](#); [9.4 Drug-Drug Interactions](#); [5 OVERDOSAGE](#)).
- during the acute recovery period following myocardial infarction.

3 SERIOUS WARNINGS AND PRECAUTIONS BOX

Serious Warnings and Precautions

Increased risk of self-harm, harm to others, suicidal thinking and behaviour with antidepressant use. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of agitation-type and/or suicidal thoughts and behaviors (see [7 WARNINGS AND PRECAUTIONS, Potential Association with Behavioural and Emotional Changes, Including Self-Harm](#)).

4 DOSAGE AND ADMINISTRATION

4.1 Dosing Considerations

- NORTRIPTYLINE is not recommended for use in children (see [1.1 Pediatrics](#); [7.1.3 Pediatrics](#)).
- NORTRIPTYLINE is contraindicated for concomitant use with MAO inhibitors (see [2 CONTRAINDICATIONS](#)). NORTRIPTYLINE should not be used within 14 days of initiating or discontinuing MAO inhibitors.
- Clinical findings should predominate over plasma concentrations as primary determinants of dosage changes.
- Dosage adjustments are recommended for elderly patients and adolescents (see [4.2 Recommended Dose and Dosage Adjustment](#)).
- The use of lower dosages for outpatients is more important than for hospitalized patients, who will be treated under close supervision.
- Dosages should be titrated, beginning at a low level and increasing gradually over several weeks, while carefully monitoring for clinical response and noting any evidence of intolerance. Improvement may not occur during the first few weeks or more of treatment.
- When discontinuing NORTRIPTYLINE, the dosage should be tapered gradually (see [4.2.1 Discontinuation Treatment](#); [7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance](#); [8.5 Post-Market Adverse Reactions, Withdrawal Symptoms](#)).
- Following remission, maintenance medication may be required for a long period of time at the lowest dose that will maintain remission.
- If a patient develops minor side effects, the dosage should be reduced. The drug should be discontinued promptly if adverse effects of a serious nature or allergic manifestations occur.

4.2 Recommended Dose and Dosage Adjustment

- **Adults (≥ 18 years):** The recommended dose of NORTRIPTYLINE is 25 mg, taken orally 3 to 4 times daily. When initiating treatment with NORTRIPTYLINE, dosage should begin at a low level and increase gradually, as required. Doses above 100 mg/day are not recommended.
- **Pediatrics (< 18 years):** Health Canada has not authorized an indication for pediatric use. The use of NORTRIPTYLINE in children is not recommended. When considering the use of nortriptyline in adolescents, the clinical need should outweigh the potential risks and uncertainties. Dosing in adolescents should be reduced to 30 to 50 mg/day, in divided doses (see [1.1 Pediatrics](#); [7.1.3 Pediatrics](#)).
- **Geriatrics:** There is limited data available involving the use of nortriptyline in patients aged 65 and over. Caution should be exercised when using NORTRIPTYLINE in elderly

patients. Dosing for elderly patients should be limited to 30 to 50 mg/day, in divided doses (see [7.1.4 Geriatrics](#)).

- **Hepatic Insufficiency:** Nortriptyline is extensively metabolized in the liver (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)). In patients with hepatic impairment, use caution when initiating treatment with NORTRIPTYLINE. Lower doses may be required.

4.2.1 Discontinuing Treatment

When discontinuing NORTRIPTYLINE, the patient should be closely monitored, while the dosage is gradually tapered over several weeks. Though not indicative of addiction, abrupt cessation of treatment following prolonged therapy may produce withdrawal symptoms, including flu-like symptoms, dizziness, nausea, headache, agitation, malaise, and abdominal cramping. As with other antidepressants, sudden discontinuation of nortriptyline treatment may also increase the risk of relapse (see [7 WARNINGS AND PRECAUTIONS, Dependence/Tolerance](#); [8.5 Post-Market Adverse Reactions, Withdrawal Symptoms](#)).

4.4 Administration

NORTRIPTYLINE is administered orally, in the form of capsules.

4.5 Missed Dose

If the patient misses a dose of NORTRIPTYLINE, the patient should be instructed to skip the missed dose and take the next dose at the regular dosing schedule.

5 OVERDOSAGE

Overdose of tricyclic antidepressants may manifest with doses as small as 50 mg in a child.

Deaths by deliberate or accidental overdose have occurred with this class of drugs. Of patients who are alive at initial presentation, a mortality rate of between 0% and 15% has been reported.

Since the propensity for suicide is high in depressed patients, a suicide attempt by other means may occur during the recovery phase.

Signs and Symptoms

Symptoms of overdose of tricyclic antidepressants may begin within several hours of oral ingestion. Symptoms and signs may include blurred vision, confusion, restlessness, dizziness, hypothermia, hyperthermia, agitation, vomiting, hyperactive reflexes, dilated pupils, fever, rapid heart rate, decreased bowel sounds, dry mouth, inability to void, myoclonic jerks, seizures, respiratory depression, myoglobinuric renal failure, nystagmus, ataxia, dysarthria, choreoathetosis, coma, hypotension, and cardiac arrhythmias.

An effect on cardiac conduction, similar to that of quinidine, may be seen with slowing of conduction, prolongation of the QRS complex and QT intervals, right bundle branch and AV block, ventricular tachyarrhythmias (including Torsade de pointes and fibrillation), and death.

Prolongation of the QRS duration to more than 0.1 seconds is predictive of more severe toxicity. The absence of sinus tachycardia does not ensure a benign course. Hypotension may be caused by vasodilation, central and peripheral alpha adrenergic blockade, and cardiac depression. In a healthy young person, prolonged resuscitation may be effective; one patient was reported to survive 5 hours of cardiac massage.

Treatment

In managing overdose, consider the possibility of multiple drug overdose, interactions among drugs, and unusual drug kinetics in your patients. Protect the patient's airway and support ventilation and perfusion. Meticulously monitor and maintain, within acceptable limits, the patient's vital signs, blood gases, serum electrolytes, etc.

Absorption of drugs from the gastrointestinal tract may be decreased by giving activated charcoal, which, in many cases, is more effective than emesis or lavage; consider charcoal instead of gastric emptying. Repeated doses of charcoal over time may hasten elimination of some drugs that have been absorbed. Safeguard the patient's airway when employing charcoal. Emesis is contraindicated.

Ventricular arrhythmias, especially when accompanied by lengthened QRS intervals, may respond to alkalization by hyperventilation or administration of sodium bicarbonate. It is important to monitor and manage serum electrolyte levels. Refractory arrhythmias may respond to propranolol, bretylium, or lidocaine.

Quinidine and procainamide usually should not be used because they may exacerbate arrhythmias and conduction already slowed by the overdose.

In patients with CNS depression early intubation is advised because of the potential for abrupt deterioration. Seizures should be controlled with benzodiazepines (e.g., diazepam), or if these are ineffective, other anticonvulsants (e.g., phenobarbital).

Since it has been reported that physostigmine may cause severe bradycardia, asystole and seizures, its use is not recommended in cases of overdose with tricyclic antidepressants. The use of phenytoin is also not recommended in cases of overdose with tricyclic antidepressants.

Diuresis and dialysis remove little of the tricyclic antidepressant present in the body of a patient who has taken an overdose. Hemoperfusion is of unproven benefit. The patient who has taken a tricyclic antidepressant overdose should be monitored closely, at least until the QRS duration is normal.

For management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).
--

6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING

Table 1 – Dosage Forms, Strengths, Composition and Packaging

Route of Administration	Dosage Form / Strength / Composition	Non-medicinal Ingredients
Oral	Capsules, 10 mg, 25 mg	Corn starch, D&C yellow #10, FD&C yellow #6, gelatin, lactose, stearic acid, talc and titanium dioxide

NORTRIPTYLINE 10 mg Capsules: Each white, opaque body, maize opaque cap, hard gelatin capsule, imprinted “NT” and “10mg” over “709”, with a white to off-white powder fill, contains nortriptyline hydrochloride equivalent to 10 mg nortriptyline base.

NORTRIPTYLINE 25 mg Capsules: Each white, opaque body, maize opaque cap, hard gelatin capsule, imprinted “NT” and “25mg” over “710”, with white to off-white powder fill, contains nortriptyline hydrochloride equivalent to 25 mg nortriptyline base.

Tartrazine-free. Available in bottles of 100, 250, 500 and 1000 capsules.

7 WARNINGS AND PRECAUTIONS

Please see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#).

General

Dental Effects: Prolonged treatment with tricyclic antidepressants can lead to an increased incidence in dental caries.

Cardiovascular

NORTRIPTYLINE is contraindicated in the acute recovery period following myocardial infarction (see [2 CONTRAINDICATIONS](#)).

Patients with cardiovascular disease should be given nortriptyline only under close supervision because of the tendency of the drug to produce sinus tachycardia and to prolong the conduction time (see [8.5 Post-Market Adverse Reactions, Cardiac disorders](#)). Myocardial infarction, arrhythmia and strokes have occurred. (See [8.5 Post-Market Adverse Reactions, Cardiac disorders](#)).

The antihypertensive action of guanethidine and similar agents may be blocked with concomitant use of nortriptyline (see [9.4 Drug-Drug Interactions](#)).

Great care is required if nortriptyline is administered to hyperthyroid patients or those receiving thyroid medication, because cardiac arrhythmias may develop (see [9.4 Drug-Drug Interactions](#)).

There have been post-marketing reports of an association between treatment with

nortriptyline and the unmasking of Brugada syndrome. Brugada syndrome is a disorder characterized by syncope, abnormal electrocardiographic (ECG) findings, and a risk of sudden death. NORTRIPTYLINE should generally be avoided in patients with Brugada syndrome or those suspected of having Brugada syndrome.

Dependence/Tolerance

Though not indicative of addiction, abrupt cessation of treatment following prolonged therapy may produce withdrawal symptoms, including flu-like symptoms, dizziness, nausea, headache, agitation, malaise, and abdominal cramping. As with other antidepressants, sudden discontinuation of nortriptyline treatment may also increase the risk of relapse. When discontinuing NORTRIPTYLINE, the patient should be closely monitored, while the dosage is gradually tapered over several weeks (see [4.1 Dosing Considerations](#); [4.2.1 Discontinuation Treatment](#); [8.5 Post-Market Adverse Reactions, Withdrawal Symptoms](#)).

Driving and Operating Machinery

Nortriptyline may cause somnolence, dizziness, and confusion. Exercise caution when driving or operating a vehicle or potentially dangerous machinery.

Endocrine and Metabolism

In hyperthyroid patients or those receiving thyroid medication, NORTRIPTYLINE may cause cardiac arrhythmias (see [8.5 Post-Market Adverse Reactions, Cardiac disorders](#); [9.4 Drug-Drug Interactions](#)).

Nortriptyline may affect blood sugar levels. Both elevation and lowering of blood sugar levels have been reported with nortriptyline (see [8.5 Post-Market Adverse Reactions, Investigations](#)). A case of significant hypoglycemia has been reported in a Type II diabetic patient maintained on chlorpropamide (250 mg/day) after the addition of nortriptyline (125 mg/day).

Those patients with reduced activity of drug metabolizing enzymes, such as the cytochrome P450 isoenzyme P450 2D6 (debrisoquin hydroxylase), may have higher plasma concentrations of nortriptyline when given usual doses. These patients may require lower doses than usually prescribed for NORTRIPTYLINE (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)).

Hyponatremia and/or syndrome of inappropriate antidiuretic hormone secretion may occur with tricyclic antidepressants, including nortriptyline (see [8.1 Adverse Reaction Overview](#); [8.5 Post-Market Adverse Reactions](#)). Elderly patients, patients taking diuretics, and patients who are otherwise volume depleted, may be at greater risk for this event.

Lactose: NORTRIPTYLINE contains lactose monohydrate. Patients with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this product.

Gastrointestinal

NORTRIPTYLINE should be used with caution in patients with pylorus stenosis and paralytic ileus.

Tricyclic antidepressants may give rise to paralytic ileus, particularly in elderly and in hospitalized patients. The risk may be increased in patients concurrently taking anticholinergic drugs. Close supervision and careful adjustment of dosage are required in this situation (see [9.4 Drug-Drug Interactions](#)). Appropriate measures should be taken if constipation occurs.

Genitourinary

Due to its anticholinergic activity, nortriptyline may cause urinary retention (see [8.5 Post-Market Adverse Reactions, Renal](#)). Extreme caution should be used when NORTRIPTYLINE is given to patients with a history of urinary retention, particularly in the presence of prostatic enlargement. Close supervision and careful adjustment of the dosage are required when nortriptyline is used with other anticholinergic drugs (see [9.4 Drug-Drug Interactions](#)).

Hematologic

Isolated cases of bone marrow depression, including agranulocytosis, leukopenia, eosinophilia, purpura, thrombocytopenia, have been reported with tricyclic antidepressants (see [8.5 Post-Market Adverse Reactions](#)).

Nortriptyline should be used with caution in patients with a history of blood disorders. Periodic monitoring of leukocyte and differential blood cell counts is recommended in these patients.

Concomitant Use with Coumarin Drugs: Tricyclic antidepressants may potentiate the anticoagulant effect of coumarin drugs (e.g., warfarin). Careful monitoring of plasma prothrombin is recommended when NORTRIPTYLINE is initiated or discontinued in patients concomitantly treated with coumarin drugs.

Monitoring and Laboratory Tests

Plasma concentrations are difficult to measure. Healthcare professionals should consult with laboratory professional staff. Clinical findings should predominate over plasma concentration as primary determinants of dosage change (see [4.1 Dosing Considerations](#)).

Musculoskeletal

Exposure to tricyclic antidepressants may increase the risk of bone fracture. The possibility of fracture should be considered in the care of patients treated with NORTRIPTYLINE. Elderly patients and patients with important risk factors for bone fractures should be advised of possible adverse events which increase the risk of falls, such as dizziness and orthostatic hypotension.

Neurologic

Seizures: Nortriptyline is known to lower convulsive threshold. Extreme caution should be exercised when using NORTRIPTYLINE in patients with a history of seizures. Patients should be followed closely when nortriptyline is administered in these patients.

Troublesome patient hostility may be aroused by the use of nortriptyline. Epileptiform seizures

may accompany its administration, as may happen with other drugs of its class.

Serotonin toxicity/Serotonin syndrome: Serotonin toxicity, also known as serotonin syndrome, is a potentially life-threatening condition and has been reported with tricyclic antidepressants.

Serotonin toxicity is characterized by neuromuscular excitation, autonomic stimulation (e.g. tachycardia, flushing) and altered mental state (e.g. anxiety, agitation, hypomania). In accordance with the Hunter Criteria, serotonin toxicity diagnosis is likely when, in the presence of at least one serotonergic agent, one of the following is observed:

- Spontaneous clonus
- Inducible clonus or ocular clonus with agitation or diaphoresis
- Tremor and hyperreflexia
- Hypertonia and body temperature >38°C and ocular clonus or inducible clonus

If concomitant treatment with NORTRIPTYLINE and other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases (see [2 CONTRAINDICATIONS](#); [4.1 Dosing Considerations](#); [9.4 Drug-Drug Interactions](#)). If serotonin toxicity is suspected, discontinuation of the serotonergic agents should be considered.

Electroconvulsive Therapy (ECT): There is limited clinical experience in the concurrent administration of ECT and antidepressant drugs. When it is essential, NORTRIPTYLINE may be administered concurrently with ECT, if such treatment is essential. However, the possibility of increased risk, relative to benefits, should be considered. Discontinue the drug for several days, if possible, prior to ECT.

Ophthalmologic

Angle-Closure Glaucoma: As with other antidepressants, NORTRIPTYLINE can cause mydriasis, which may trigger an angle-closure attack in a patient with anatomically narrow ocular angles. Healthcare providers should inform patients to seek immediate medical assistance if they experience eye pain, changes in vision or swelling or redness in or around the eye.

Anticholinergic effects: Due to anticholinergic activity, nortriptyline may cause an increase in intraocular pressure. NORTRIPTYLINE should not be used in patients with or at risk of glaucoma (see [8.1 Adverse Reaction Overview](#)).

Decreased lacrimation and accumulation of mucoid secretions, due to the anticholinergic properties of tricyclic antidepressants, may cause damage to the corneal epithelium in patients with contact lenses.

Peri-Operative Considerations

NORTRIPTYLINE should be discontinued as soon as possible (for several days, if possible) prior to elective surgery due to possible drug interactions and cardiovascular effects (see [8.5 Post-](#)

[Market Adverse Reactions, Cardiac disorders; 9.4 Drug-Drug Interactions](#)).

Anesthetics given during tricyclic antidepressant therapy may increase the risk of arrhythmias and hypotension. NORTRIPTYLINE should be discontinued several days before elective surgery if possible.

Psychiatric

Potential Association with Behavioural and Emotional Changes, Including Self-Harm:

Pediatrics: Placebo-Controlled Clinical Trial Data

Recent analyses of placebo-controlled clinical trial safety databases from SSRIs and other newer antidepressants suggest that use of these drugs in patients under the age of 18 may be associated with behavioural and emotional changes, including an increased risk of suicidal ideation and behaviour over that of placebo.

The small denominators in the clinical trial database, as well as the variability in placebo rates, preclude reliable conclusions on the relative safety profiles among the drugs in the class.

Adults and Pediatrics: Additional data

There are clinical trial and post-marketing reports with SSRIs and other newer antidepressants, in both pediatrics and adults, of severe agitation-type adverse events coupled with self-harm or harm to others. The agitation-type events include: akathisia/psychomotor restlessness, agitation, disinhibition, emotional lability, hostility, aggression, depersonalization. In some cases, the events occurred within several weeks of starting treatment.

Rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages. This includes monitoring for agitation-type emotional and behavioural changes.

An FDA meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients ages 18 to 24 years with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo.

All patients being treated with antidepressants should be monitored appropriately and observed closely for clinical worsening, suicidality, and unusual changes in behaviour, especially during the initial few months of a course of drug therapy, or at times of dose changes, either increases or decreases.

Symptoms of anxiety, agitation, panic attacks, insomnia, irritability, hostility (aggressiveness), impulsivity, akathisia (psychomotor restlessness), hypomania and mania have been reported in adults, adolescents and children being treated with antidepressants for major depressive disorder as well as for other indications, both psychiatric and nonpsychiatric. Closely monitor all antidepressant-treated patients for clinical worsening and for emergence of agitation-type and/or suicidal thoughts and behaviors (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#)).

Inform the patient that their response to alcohol may be exaggerated. Excessive consumption of alcohol in combination with nortriptyline therapy may have a potentiating effect, which may increase the risk of suicidal thinking and behaviour (see [3 SERIOUS WARNINGS AND PRECAUTIONS BOX](#)) and/or overdose, especially in patients with a history of emotional disturbances or suicidal ideation (see [9.3 Drug-Behavioural Interactions](#)).

The possibility of a suicidal attempt by depressed patients remains even after initiation of treatment. In this regard, it is important that the least possible quantity of drug be dispensed at any given time.

Psychosis, Mania/Hypomania and Other Neuropsychiatric Phenomena: The use of nortriptyline in schizophrenic patients may result in an exacerbation of the psychosis or may activate latent schizophrenic symptoms. If the drug is given to overactive or agitated patients, increased anxiety and agitation may occur. In manic depressive patients, nortriptyline may cause symptoms of the manic phase to emerge.

Renal

NORTRIPTYLINE should be used with caution in patients with tumors of the adrenal medulla (e.g., pheochromocytoma, neuroblastoma), in whom the drug may provoke a hypertensive crisis.

Skin

Rare cases of drug reaction with eosinophilia and systemic symptoms (DRESS), a potentially life-threatening adverse drug reaction, have been reported with the use of tricyclic antidepressants, including nortriptyline. DRESS consists of a combination of three or more of the following: cutaneous reaction (such as rash or exfoliative dermatitis), eosinophilia, fever, lymphadenopathy and one or more systemic complications such as hepatitis, nephritis, pneumonitis, myocarditis, and pericarditis. If DRESS is suspected, discontinue NORTRIPTYLINE immediately.

7.1 Special Populations

7.1.1 Pregnant Women

Nortriptyline is known to cross the placenta barrier. Safe use of nortriptyline during pregnancy has not been established; therefore, when the drug is administered to pregnant patients, or women of childbearing age, the potential benefits must be weighed against the possible hazards (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)). Animal reproduction studies have yielded inconclusive results.

Exposure to tricyclic antidepressants in mid to late pregnancy may increase the risk for preeclampsia.

Withdrawal symptoms including tremors, lethargy, colic, irritability, hypotonia/hypertonia, convulsions, poor suckling reflex, irregular breathing, respiratory depression, and possibly anticholinergic symptoms (urinary retention and constipation) have been reported in neonates whose mother received tricyclic antidepressants during the third trimester of pregnancy.

7.1.2 Breast-feeding

Nortriptyline is present in breast milk. Safe use of nortriptyline during lactation has not been established; therefore, when the drug is administered to nursing mothers, the potential benefits must be weighed against the possible hazards (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)).

7.1.3 Pediatrics

Pediatrics (<18 years): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NORTRIPTYLINE in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. Nortriptyline is not recommended for use in children (see [1.1 Pediatrics](#)).

7.1.4 Geriatrics

There is limited data available involving the use of nortriptyline in patients aged 65 and over. Elderly patients may respond differently to NORTRIPTYLINE and may be more liable to experience adverse reactions, especially agitation, confusion and postural hypotension.

Higher plasma concentrations of the active nortriptyline metabolite, 10-hydroxynortriptyline, have also been reported in elderly patients, associated with apparent cardiotoxicity (see [10.3 Pharmacokinetics, Special Populations and Conditions](#)). Cardiovascular function, particularly arrhythmias and fluctuations in blood pressure, should be monitored.

There have been reports of confusional states following tricyclic antidepressant administration to the elderly (see [8.5 Post-Market Adverse Reactions, Psychiatric disorders](#)). Dose selection for an elderly patient should usually be limited to the smallest effective total daily dose (see [4.2 Recommended Dose and Dosage Adjustment](#)).

8 ADVERSE REACTIONS

8.1 Adverse Reaction Overview

Clinical trial data on which the indication was originally authorized is not available. Adverse reactions associated with nortriptyline use are listed in [8.5 Post-Market Adverse Reactions](#).

The most serious adverse effects include orthostatic hypotension, syncope, ventricular arrhythmias, AV block, myocardial infarction, stroke, paralytic ileus, glaucoma, increased intraocular pressure, agranulocytosis, leukopenia, thrombocytopenia, hepatitis, angioedema.

8.2 Clinical Trial Adverse Reactions

The clinical trial data on which the indication was originally authorized is not available. See [8.5 Post-Market Adverse Reactions](#), below.

8.3 Less Common Clinical Trial Adverse Reactions

The clinical trial data on which the indication was originally authorized is not available.

8.4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data

The clinical trial data on which the indication was originally authorized is not available.

8.5 Post-Market Adverse Reactions

Note: Included in the following list are a few adverse reactions that have not been reported with this specific drug. However, the pharmacologic similarities among the tricyclic antidepressant drugs require that each of these reactions be considered when nortriptyline is administered.

Blood and lymphatic system disorders: bone marrow depression, including agranulocytosis, aplastic anemia, eosinophilia, purpura, thrombocytopenia, leukopenia.

Cardiac disorders: tachycardia, palpitation, myocardial infarction, arrhythmias, heart block, QT prolongation (especially in the elderly), Brugada syndrome, changes in AV conduction, asystole, syncope, ventricular tachycardia, fibrillation, unexpected death in patients with cardiovascular disorders.

Endocrine disorders: gynecomastia in the male; syndrome of inappropriate ADH (antidiuretic hormone) secretion.

Eye disorders: angle-closure glaucoma, blurred vision, disturbance of accommodation, mydriasis, precipitation of latent glaucoma, aggravation of existing glaucoma. Nortriptyline hydrochloride can cause mild pupillary dilation, which in susceptible individuals, can lead to an episode of angle-closure glaucoma.

Gastrointestinal disorders: nausea and vomiting, epigastric distress, diarrhea, peculiar taste, stomatitis, abdominal cramps, black tongue, constipation, paralytic ileus, dry mouth and, rarely, associated sublingual adenitis or gingivitis, parotid swelling, heartburn.

General disorders and administration site conditions: weakness, fatigue, drug fever, perspiration, flushing, jitteriness.

Hepatobiliary disorders: jaundice (simulating obstructive), altered liver function, hepatitis, liver necrosis.

Immune system disorders: edema (general or face and tongue), cross - sensitivity with other tricyclic drugs.

Investigations: alteration of electroencephalogram (EEG) patterns, elevation or depression of blood sugar levels, weight gain or loss, increased intraocular pressure, non-specific ECG changes, prolonged conduction time, QT interval prolongation, elevation.

Metabolism and nutrition disorders: anorexia, hyponatremia.

Musculoskeletal and connective tissue disorders: lupus-like syndrome (migratory arthritis, positive ANA and rheumatoid factor).

Nervous system disorders: numbness, tingling, paresthesia of extremities; incoordination, ataxia, tremor; peripheral neuropathy, extrapyramidal symptoms; seizures; tinnitus; headache;

drowsiness, dizziness, coma, dysarthria, slurred speech, giddiness and ageusia.

Psychiatric disorders: confusional state (especially in the elderly) with hallucinations, disorientation, delusions; anxiety, restlessness, agitation; insomnia, panic, nightmares; hypomania; exacerbation of psychosis, activation of latent schizophrenia, excitement.

Renal and urinary disorders: urinary retention, delayed micturition, dilatation of the urinary tract, urinary frequency, nocturia.

Reproductive system and breast disorders: breast enlargement and galactorrhea in the female; increased or decreased libido, impotence; testicular swelling.

Skin and subcutaneous tissue disorders: skin rash, petechiae, urticaria, itching, photosensitization (avoid excessive exposure to sunlight), alopecia, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Vascular disorders: hypotension, hypertension, stroke.

Withdrawal Symptoms: though these are not indicative of addiction, abrupt cessation of treatment after prolonged administration may produce flu-like symptoms, dizziness, nausea, headache, agitation, malaise, and abdominal cramping. Relapse of depression and anxiety may also occur.

9 DRUG INTERACTIONS

9.1 Serious Drug Interactions

Serious Drug Interactions

- Concomitant use of NORTRIPTYLINE with monoamine oxidase (MAO) inhibitors, such as linezolid, and IV methylene blue, is contraindicated as it can lead to an increased risk of developing serotonin toxicity, which can be life-threatening (see [2 CONTRAINDICATIONS](#); [7 WARNINGS AND PRECAUTIONS, Neurologic](#); [9.4 Drug-Drug Interactions](#)).

9.2 Drug Interactions Overview

Concomitant use of NORTRIPTYLINE with monoamine oxidase (MAO) inhibitors is contraindicated (see [2 CONTRAINDICATIONS](#)). NORTRIPTYLINE should not be co-administered with, or within 2 weeks of, a MAO inhibitor drug (see [9.4 Drug-Drug Interactions](#)).

Concomitant use of nortriptyline with other serotonergic agents, particularly MAO inhibitors, increases the risk of serotonin toxicity (see [9.4 Drug-Drug Interactions](#)).

Prescribe NORTRIPTYLINE with extreme caution for hyperthyroid patients or for patients receiving thyroid medication. Transient cardiac arrhythmias have occurred in rare instances in patients who have been receiving other tricyclic compounds concomitantly with thyroid medication (see [9.4 Drug-Drug Interactions](#)).

NORTRIPTYLINE has anticholinergic actions. Close supervision and careful adjustment of dosage are required when this drug is administered concomitantly with other anticholinergic or

sympathomimetic drugs (see [9.4 Drug-Drug Interactions](#)).

NORTRIPTYLINE may decrease the effect of drugs that rely upon neuronal uptake via the norepinephrine transporter, such as the antihypertensive, guanethidine (see [9.4 Drug-Drug Interactions](#)).

Co-administration of tricyclic antidepressants with other drugs that are metabolized by the cytochrome P450 isoenzyme CYP2D6, including other antidepressants, phenothiazines, carbamazepine, and Type 1C antiarrhythmics (e.g., propafenone, flecainide, and encainide), or that inhibit this enzyme (e.g. quinidine), should be approached with caution (see [7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism](#)).

Nortriptyline can exaggerate the response to alcohol (see [9.3 Drug-Behavioural Interactions](#)).

9.3 Drug-Behavioural Interactions

The patient should be warned their response to alcohol may be exaggerated (see [7 WARNINGS AND PRECAUTIONS, Psychiatric](#)).

9.4 Drug-Drug Interactions

The drugs listed in this table are based on either drug interaction case reports or studies, or potential interactions due to the expected magnitude and seriousness of the interaction (i.e., those identified as contraindicated).

Table 2 - Established or Potential Drug-Drug Interactions

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
MAO inhibitors (e.g., selegiline, phenelzine, linezolid, iv methylene blue)	CT	Increase in nortriptyline exposure.	The concomitant use of NORTRIPTYLINE or other tricyclic antidepressants with a MAO inhibitor is contraindicated, as it can lead to an increased risk of developing serotonin toxicity, which can be life-threatening. NORTRIPTYLINE should not be used within 14 days of initiating or discontinuing MAO inhibitors (see 2 CONTRAINDICATIONS ; 7 WARNINGS AND PRECAUTIONS, Neurologic ; 9.1 Serious Drug Interactions).

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
Serotonergic drugs (e.g., triptans, tricyclic antidepressants, SSRIs, SNRIs, fentanyl, lithium, tramadol, tryptophan, buspirone)	CT	Potentiated serotonin levels. Possible increase in nortriptyline exposure.	The concomitant use of nortriptyline with other serotonergic drugs increases the risk of serotonin toxicity (see 7 WARNINGS AND PRECAUTIONS, Neurologic). If concomitant treatment with NORTRIPTYLINE and other serotonergic agents is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases and when switching from one class to the other.
Fluoxetine	CT	>2 fold increase in nortriptyline exposure	Fluoxetine and its active metabolite, norfluoxetine, have a long half-life (7 to 9 days for norfluoxetine) which might affect strategies during conversion from one drug to another.
Reserpine (adrenergic blocking agent)	C	Increase in nortriptyline exposure.	Administration of reserpine during therapy with a tricyclic antidepressant has been shown to produce a “stimulating” effect in some depressed patients.

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
Histamine H2 blockers (e.g., cimetidine)	CT	Increase in nortriptyline exposure.	Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) may occur (see 7 WARNINGS AND PRECAUTIONS, Genitourinary; 7 WARNINGS AND PRECAUTIONS, Ophthalmologic). The therapeutic efficacy of NORTRIPTYLINE may be compromised, upon cimetidine discontinuation.
Anticholinergic drugs	T	↑ Anticholinergic effects	Tricyclic antidepressants may potentiate the effects of anticholinergic drugs on the eye, central nervous system, bowel and bladder. Close supervision and careful adjustment of dosage are required. Paralytic ileus, urinary retention or acute glaucoma may occur in patients taking tricyclic antidepressants in combination with anticholinergic-type drugs, particularly in elderly or hospitalized patients.
	CT	Hyperpyrexia	NORTRIPTYLINE for enuresis should not be combined with an anticholinergic drug. Hyperpyrexia has been reported when tricyclic antidepressants are administered with anticholinergic agents, particularly during hot weather.

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
Sympathomimetic drugs (as found in anesthetics) (e.g., adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine)	CT	Increased pressor response to sympathomimetics.	May produce severe hypertension (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular). Concomitant use with sympathomimetic agents is not recommended. Close supervision and careful adjustment of the dosage are required.
Antihypertensives (e.g., guanethidine, debrisoquine, betanidine, methyldopa, clonidine)	T	Reduced uptake of antihypertensive drugs.	NORTRIPTYLINE may decrease the efficacy of antihypertensive drugs (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).
Thyroid medications (e.g., levothyroxine)	C	Mutual effects on exposure.	The risk or severity of adverse reactions associated with either drug may be increased. Cardiac arrhythmias may develop (see 7 WARNINGS AND PRECAUTIONS, Cardiovascular).
Phenothiazines (e.g., chlorpromazine, thioridazine, trifluoperazine)	T	Increase in nortriptyline exposure.	Use caution with concomitant use. Dosage adjustments may be required.
Carbamazepine	CT	Reduced nortriptyline exposure.	May reduce the efficacy of nortriptyline.

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
Type 1C antiarrhythmics (e.g., quinidine)	CT	>2 fold increase in nortriptyline exposure	Concomitant use increases the risk of serotonin toxicity and anticholinergic symptoms and should be avoided (see 7 WARNINGS AND PRECAUTIONS, Neurologic ; 9.2 Drug Interactions Overview).
Valproic acid	C	↑ nortriptyline exposure	Clinical monitoring is recommended
	T	↑ Seizures	Concomitant use with tricyclic antidepressants may lower the seizure threshold. Dosage adjustment for valproic acid may be necessary to control seizures.
Baclofen	T	↑ muscle relaxant effect	Tricyclic antidepressants, such as NORTRIPTYLINE, may enhance the muscle relaxant effect of baclofen.
Coumarin drugs (e.g., warfarin)	T	↑ Anticoagulant effect	Tricyclic antidepressants may potentiate the anticoagulant effect of coumarin drugs. Careful monitoring of plasma prothrombin is recommended.
Iobenguane	T	Inaccurate imaging results	Antidepressants that inhibit the function of the norepinephrine transporter, such as nortriptyline, have the potential to interfere with iobenguane imaging results. Before iobenguane administration, drugs known or expected to interfere with iobenguane uptake should be discontinued, as clinically tolerated.

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
Neuroleptics (e.g., phenothiazines [fluphenazine, thioridazine ^a], butyrophenones [haloperidol])	T	<p>↑ Seizures</p> <p>↑ risk of cardiac side effects</p>	<p>Tricyclic antidepressants and neuroleptics mutually inhibit the metabolism of each other. This may result in increased tricyclic antidepressant and neuroleptic plasma level, a lowered convulsion threshold, and seizures. It may be necessary to adjust the dosage of these drugs.</p> <p>Combination with thioridazine may also cause cardiac arrhythmias. Co-administration of NORTRIPTYLINE and thioridazine should be avoided.</p>
	CT	Hyperpyrexia	Hyperpyrexia has been reported when tricyclic antidepressants are administered with neuroleptic drugs, particularly during hot weather.
Nitrates (e.g., nitroglycerin)	T	Severe hypotension	Nitrates should be used with caution in combination with tricyclic antidepressants, as it may lead to an augmentation of the hypotensive effect of nitrates. Clinical monitoring is recommended, and dose adjustment may be required.
		↓ Sublingual nitrates	Because of their anticholinergic properties, tricyclic antidepressants can cause dry mouth, which may decrease the absorption of sublingual nitrates.

Proper / Common name	Source of Evidence	Potential Effect	Clinical comment
Opioids (e.g., buprenorphine, methadone, tramadol)	T	<p>↑ Risk for serotonin toxicity, urinary retention, and constipation</p> <p>↑ Risk for seizures and opioid toxicity with concomitant use of tramadol.</p>	<p>Concomitant use of tricyclic antidepressants, and opioids, such as buprenorphine, methadone and tramadol, may increase the risk of serotonin toxicity, a potentially life-threatening condition. Concomitant use with opioids may also increase the risk for urinary retention and constipation.</p> <p>Concomitant use of tricyclic antidepressants and tramadol also increases the risk for seizures. In addition, this combination can inhibit the metabolism of tramadol to the active metabolite and thereby increasing tramadol concentrations, potentially causing opioid toxicity.</p>
Pitolisant	T	↓ effectiveness of pitolisant	Pitolisant increases the level of histamine in the brain. Concomitant use of tricyclic antidepressants with H1 receptor antagonist properties, should be avoided.
Sympathomimetic drugs	T	↑ Cardiovascular effects	Tricyclic antidepressants may potentiate the cardiovascular effects of sympathomimetic drugs. Close supervision and careful adjustment of dosage are required when nortriptyline is administered with sympathomimetic drugs, including epinephrine combined with local anesthetics.

^a No longer marketed in Canada

Legend: C = Case Study; CT = Clinical Trial; T = Theoretical

Cytochrome P450 inhibitors: Certain drugs that inhibit the activity of CYP2D6 make normal metabolizers resemble poor metabolizers. A given dose of tricyclic antidepressant may become abruptly toxic when a drug that inhibits CYP2D6 is introduced as concomitant therapy.

The drugs that inhibit CYP2D6 include some that are not metabolized by the enzyme such as cimetidine, quinidine, bupropion, duloxetine, fluoxetine, paroxetine and terbinafine, and many that are substrates for CYP2D6 such as many other antidepressants, phenothiazines (see [Table 2](#) above), and the Type 1C antiarrhythmics propafenone and flecainide.

Cimetidine (which is also a CYP1A2 and CYP3A4 inhibitor) has been reported to reduce hepatic metabolism of certain tricyclic antidepressants, thereby delaying elimination and increasing steady-state concentrations of these drugs. Clinically significant effects have been reported with the tricyclic antidepressants when used concomitantly with cimetidine. Increases in plasma levels of tricyclic antidepressants, and in the frequency and severity of side effects, particularly anticholinergic, have been reported when cimetidine was added to the drug regimen.

Antifungals such as fluconazole (CYP2C9, CYP2C19 and CYP3A4 inhibitor) and terbinafine have also been observed to increase serum levels tricyclic antidepressants, and accompanying toxicity. Syncope and torsade de pointes have occurred.

Cytochrome P450 inducers: Oral contraceptives, rifampicin, phenytoin, barbiturates, and carbamazepine may increase the metabolism of tricyclic antidepressants, resulting in lowered plasma levels of tricyclic antidepressants and reduced antidepressant response. In addition, nortriptyline may increase plasma levels of carbamazepine and phenytoin. Dosage adjustment of these drugs may be necessary.

Serotonergic agents: While selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit CYP2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs as well as in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).

QT-prolonging drugs: Concomitant use of drugs that prolong the QT interval with tricyclic antidepressants such as NORTRIPTYLINE may increase the likelihood of ventricular arrhythmias.

Drugs that have been associated with QT/QTc interval prolongation and/or torsade de pointes include, but are not limited to, the examples in the following list. Chemical/pharmacological classes are listed if some, although not necessarily all, class members have been implicated in QT/QTc prolongation and/or torsade de pointes:

- Class IA antiarrhythmics (e.g., quinidine, procainamide, disopyramide);
- Class III antiarrhythmics (e.g., amiodarone);
- Class 1C antiarrhythmics (e.g., flecainide, propafenone);
- antipsychotics (e.g., pimozide, haloperidol);

- antidepressants (e.g., fluoxetine, tricyclic/tetracyclic antidepressants);
- opioids (e.g., methadone);
- macrolide antibiotics and analogues (e.g., erythromycin, clarithromycin, tacrolimus);
- quinolone antibiotics (e.g., ciprofloxacin);
- antimalarials (e.g., quinine, chloroquine);
- azole antifungals (e.g., ketoconazole);
- domperidone;
- 5-HT₃ receptor antagonists (e.g., ondansetron);
- tyrosine kinase inhibitors (e.g., sunitinib);
- histone deacetylase inhibitors (e.g., vorinostat);
- beta-2 adrenoceptor agonists (e.g., salmeterol).

The above list of potentially interacting drugs is not comprehensive. Current information sources should be consulted for newly approved drugs that prolong the QT/QTc interval as well as for older drugs for which these effects have recently been established.

9.5 Drug-Food Interactions

Interactions with food have not been established.

9.6 Drug-Herb Interactions

Interactions with herbal remedies have not been established.

Herbal remedies such as milk thistle, kava kava, black cohosh, Echinacea, and St. John's wort are mild modulators of human CYP2D6 and not expected to significantly alter nortriptyline exposure. However, exercise caution when using these herbal remedies with NORTRIPTYLINE. Goldenseal should be avoided while taking NORTRIPTYLINE, as it is a potent CYP2D6 inhibitor and may give rise to significant pharmacokinetic herb-drug interactions, resulting in increased adverse reactions.

Herbal remedies known to regulate serotonin, such as St. John's wort, Garcinia cambogia (HCA), and ashwagandha should be avoided, as concomitant use may increase the risk of serotonin toxicity (see [7 WARNINGS AND PRECAUTIONS, Neurologic](#)).

9.7 Drug-Laboratory Test Interactions

Interactions with laboratory tests have not been established.

10 CLINICAL PHARMACOLOGY

10.1 Mechanism of Action

The mechanism of mood elevation of tricyclic antidepressants is at present unknown. NORTRIPTYLINE (nortriptyline hydrochloride) is not an MAO inhibitor. It inhibits the activity of such diverse agents as histamine, 5-hydroxytryptamine, and acetylcholine. It increases the pressor effect of norepinephrine but blocks the pressor response of phenethylamine. Studies suggest that nortriptyline hydrochloride interferes with the transport, release, and storage of catecholamines.

10.2 Pharmacodynamics

There are post-marketing reports of QT prolongation, particularly in the elderly (see [8.5 Post-Market Adverse Reactions, Cardiac disorders](#)).

10.3 Pharmacokinetics

Absorption

Nortriptyline HCl is well absorbed from the GI tract. Plasma concentrations exhibit considerable inter-patient variation. A relationship of plasma concentrations to clinical response and acute toxicity has not been fully established but has been reported by other study groups. Peak plasma concentrations occur within 7 to 8.5 hours after oral administration. Optimal response to the drug appears to be associated with plasma concentrations of 50 to 150 ng/mL. Adverse effects appear within a few hours after administration of the drug, but full antidepressant effects may not occur for several weeks.

Distribution

Nortriptyline HCl is distributed to the lungs, heart, brain, and liver. Nortriptyline and its metabolite are highly bound to plasma and tissue proteins. Nortriptyline readily crosses the placenta and is distributed into breast milk where it appears in similar or slightly greater concentrations than those present in the maternal serum.

Metabolism

Nortriptyline is subject to extensive first-pass metabolism in the liver by CYP2D6 to its active metabolite, 10-hydroxynortriptyline, which is active.

Elimination

Nortriptyline, when administered orally, undergoes first-pass metabolism in the liver. The primary route of elimination is urinary excretion, approximately one-third of the dose as metabolites within 24 hours, but it is also excreted in feces via the bile. The plasma half-life of nortriptyline ranges from 16 to more than 90 hours.

Special Populations and Conditions

- **Pediatrics (<18 yrs):** Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NORTRIPTYLINE in pediatric patients has not been established. Therefore, Health Canada has not authorized an indication for pediatric use.
- **Geriatrics:** There is limited data available involving the use of nortriptyline in patients aged 65 and over. However, elderly patients may be more sensitive to the effects of tricyclic antidepressants. Dosing adjustments are recommended (see [4.2 Recommended Dose and Dosage Adjustment](#)). Higher plasma concentrations of the active nortriptyline metabolite, 10-hydroxynortriptyline, have also been reported in elderly patients.
- **Sex:** The data upon which the indication was originally authorized is not available.
- **Pregnancy and Breast-feeding:** Nortriptyline is known to cross the placenta. Nortriptyline should only be used in pregnancy if the potential benefits outweigh the

possible hazards (see [7.1.1 Pregnant Women](#)).

Nortriptyline is present in breast milk. The safe use of nortriptyline during breast-feeding has not been established. Nortriptyline should only be used in nursing mothers if the potential benefits outweigh the possible hazards (see [7.1.2 Breast-feeding](#)).

- **Genetic Polymorphism:** A subset (3 to 10%) of the population has reduced activity of certain drug metabolizing enzymes such as the cytochrome P450 isoenzyme P450 2D6. Such individuals are referred to as "poor metabolizers" of drugs such as debrisoquin, dextromethorphan and the tricyclic antidepressants. These individuals may have higher than expected plasma concentrations of tricyclic antidepressants when given usual doses.
- **Ethnic Origin:** The data upon which the indication was originally authorized is not available.
- **Hepatic Insufficiency:** The data upon which the indication was originally authorized is not available. However, nortriptyline is primarily metabolized in the liver and impairments in hepatic function may increase drug exposure.
- **Renal Insufficiency:** The data upon which the indication was originally authorized is not available.
- **Obesity:** The data upon which the indication was originally authorized is not available.

11 STORAGE, STABILITY AND DISPOSAL

Store at room temperature (15°C - 30°C). Keep tightly closed.

NORTRIPTYLINE should never be disposed of in household trash. Disposal via a pharmacy take back program is recommended.

12 SPECIAL HANDLING INSTRUCTIONS

None.

PART II: SCIENTIFIC INFORMATION


13 PHARMACEUTICAL INFORMATION

Drug Substance

- Proper Name: Nortriptyline hydrochloride
- Chemical Names: 1) 1-Propanamine, 3-(10,11-dihydro-5*H*-dibenzo-[a,d]-cyclohepten-5-ylidene)-*N*-methyl-, hydrochloride;
- 2) 10,11-Dihydro-*N*-methyl-5*H*-dibenzo-[a,d]-cycloheptene- $\Delta^{5,\nu}$ -propylamine hydrochloride.

Molecular Formula and Molecular Mass: $C_{19}H_{21}N \cdot HCl$ and 299.84 g/mol

Structural formula:



Physicochemical properties: Nortriptyline hydrochloride is a white to off-white powder, having a slight, characteristic odor. Its solution (1 in 100) has a pH of about 5. Soluble in water and in chloroform; sparingly soluble in methanol; practically insoluble in ether, in benzene, and in most other organic solvents.

14 CLINICAL TRIALS

14.1 Clinical Trials by Indication

The data upon which the indication was originally authorized is not available.

14.2 Comparative Bioavailability Studies

A randomized, two-treatment, two-period, single-dose, crossover comparative bioavailability study of NORTRIPTYLINE 25 mg capsules (Apotex Inc.) and Aventyl® 25 mg capsules (Eli Lilly Canada Inc.) was conducted in healthy adult male subjects under fasting conditions. Comparative bioavailability data from 16 subjects that were included in the statistical analysis are presented in the following table:

SUMMARY TABLE OF THE COMPARATIVE BIOAVAILABILITY DATA

Nortriptyline (3 x 25 mg) Geometric Least Square Mean Arithmetic Mean (CV%)				
Parameter	Test ¹	Reference ²	% Ratio of Geometric Means	90% Confidence Interval
AUC ₀₋₇₂ (ng·h/mL)	1188 1264 (33)	1216 1267 (33)	98	91 – 105
AUC _T (ng·h/mL)	1436 1575 (40)	1476 1593 (41)	97	91 – 104
AUC _I (ng·h/mL)	1589 1730 (40)	1683 1746 (42)	94	90 – 99
C _{max} (ng/mL)	36.76 38.36 (30)	38.50 39.27 (29)	95	85 – 107
T _{max} ³ (h)	7.9 (23)	8.0 (27)		
T _{1/2} ³ (h)	37.8 (41)	36.1 (38)		

¹ NORTRIPTYLIN (nortriptyline hydrochloride) capsules, 25 mg (Apotex Inc.)

² Aventyl® (nortriptyline hydrochloride) capsules, 25 mg (Eli Lilly Canada Inc.)

³ Expressed as the arithmetic mean (CV%) only

15 MICROBIOLOGY

No microbiological information is required for this drug product.

16 NON-CLINICAL TOXICOLOGY

The data upon which the indication was originally authorized is not available.

17 SUPPORTING PRODUCT MONOGRAPHS

1. AVENTYL® (capsules, 10 mg and 25 mg), submission control 173243, Product Monograph AA Pharma Inc. (April 29, 2014).

PATIENT MEDICATION INFORMATION

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

NORTRIPTYLINE

Nortriptyline Hydrochloride Capsules

Read this carefully before you start taking **NORTRIPTYLINE** and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about **NORTRIPTYLINE**.

Serious Warnings and Precautions

To help avoid side effects and ensure proper use, before you take NORTRIPTYLINE, talk to your healthcare professional if you:

- Are taking any other medication that may cause heart problems or affect your heart rhythm.
- Have electrolytes levels that are either too low or too high such as a low level of potassium, calcium or magnesium, or a high level of potassium in your blood. Your healthcare professional will need to treat this before you start taking NORTRIPTYLINE.
- Have a history of heart problems such as
 - changes in heart rhythm,
 - a slow heartbeat (bradycardia),
 - heart disease, including a condition called heart failure (a condition where your heart cannot pump the blood in your body as well as it should)

A heart problem called “prolonged QT interval” (which is shown on your electrocardiogram, ECG) and problems with the heart rhythm (rapid or irregular heartbeat) have been reported in people taking NORTRIPTYLINE.

NORTRIPTYLINE may also reveal a hidden heart problem you did not know you had, a problem called “Brugada Syndrome”. Before you start taking NORTRIPTYLINE, tell your healthcare professional if you have unexplained fainting or a family history of “Brugada Syndrome” or unexplained sudden death before 45 years of age, as this could indicate you may have “Brugada Syndrome”. You should not take NORTRIPTYLINE if you have or are suspected to have “Brugada Syndrome”.

These problems can be serious and cause sudden death. Get immediate medical help if you experience dizziness, fainting, a rapid heartbeat or heart palpitations while taking NORTRIPTYLINE.

- have a history of trouble emptying your bladder (urinary retention), an enlarged prostate gland, increased pressure in the eye or glaucoma as NORTRIPTYLINE can

make these conditions worse.

- have thyroid problems or are taking thyroid medication. Heart rhythm problems may develop when NORTRIPTYLINE is taken with thyroid medicines.
- have a history of seizures or fits. NORTRIPTYLINE can make you more likely to have seizures or fits.

New and worsened emotional or behaviour problems:

- When you first start taking NORTRIPTYLINE or when your dose is adjusted, you may feel worse instead of better. You may feel new or worsened feelings of agitation, hostility, anxiety, aggression or impulsivity.
- During your treatment with NORTRIPTYLINE, it is important that you and your healthcare professional talk regularly about how you are feeling. They will closely monitor you for signs of new or worsened emotions or behaviours while you are taking NORTRIPTYLINE.
- You may find it helpful to tell a relative or close friend that you are depressed. Ask them to read this leaflet. You might ask them to tell you if they:
 - think your depression is getting worse, or
 - are worried about changes in your behaviour.
- If your depression worsens or you experience changes in your behaviour, tell your healthcare professional right away. Do not stop taking your medicine as it takes time for NORTRIPTYLINE to work.

Self-harm or suicide:

- Antidepressants, such as NORTRIPTYLINE, may increase the risk of suicidal thoughts and actions.
- If you have thoughts of harming or killing yourself at any time, tell your healthcare professional or go to a hospital right away. Close observation by a healthcare professional is necessary in this situation.

What is NORTRIPTYLINE used for?

NORTRIPTYLINE is used in adults to relieve the symptoms of depression (feeling sad, a change in appetite or weight, difficulty concentrating or sleeping, feeling tired, headaches, unexplained aches and pain).

How does NORTRIPTYLINE work?

NORTRIPTYLINE is a medicine that belongs to a group of medicines known as tricyclic antidepressants. It is not known exactly how NORTRIPTYLINE works. It is thought to increase the concentration of certain chemicals in the brain which can help with the symptoms of depression.

What are the ingredients in NORTRIPTYLINE?

Medicinal ingredients: Nortriptyline hydrochloride

Non-medicinal ingredients: Corn starch, D&C yellow #10, FD&C yellow #6, gelatin, lactose, stearic acid, talc and titanium dioxide.

NORTRIPTYLINE comes in the following dosage forms:

Capsules: 10 mg and 25 mg nortriptyline (as nortriptyline hydrochloride).

Do not use NORTRIPTYLINE if:

- you are allergic to nortriptyline or any of the non-medicinal ingredients in NORTRIPTYLINE
- you are currently taking or have taken, within the last 14 days, medicines called monoamine oxidase inhibitors (MAOIs) such as phenelzine sulphate, moclobemide, tranylcypromine, linezolid, methylene blue or selegiline.
- you have recently experienced a heart attack or heart failure

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take NORTRIPTYLINE. Talk about any health conditions or problems you may have, including if you:

- have heart problems
- have low blood pressure
- have high pressure in the eyes (glaucoma)
- have or have a history of difficulty passing urine
- have an enlarged prostate gland
- have a history of epilepsy or seizures
- have a thyroid condition or are taking thyroid medication
- have schizophrenia, bipolar disorder or any other mental health problems
- are taking other anticholinergic medicines (certain medicines used to treat asthma, chronic obstructive pulmonary disease, stomach and gut problems, and Parkinson's disease) or sympathomimetic medicines such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine
- have ever had suicidal thoughts
- consume alcohol. Drinking alcohol while taking NORTRIPTYLINE may exaggerate your response to alcohol.
- are going to have electroconvulsive therapy (electric shock)
- have diabetes
- are pregnant, think you might be pregnant or are planning to become pregnant
- are breastfeeding or are planning to breastfeed
- are taking medicines used to treat high blood pressure such as guanethidine
- are 65 years of age or older
- have liver problems
- are taking medicines used to increase the amount of water released in your urine known as diuretics or "water pills"
- are dehydrated or suffer from excessive sweating, vomiting or diarrhea, or an eating disorder

- have dental problems.
- wear contact lenses.
- have a tumour (cancer) of the adrenal gland (such as pheochromocytoma or neuroblastoma).
- have or have had a blood disease such as low platelet or white blood cell counts.
- have pylorus stenosis (narrowing of the gastric outlet) and paralytic ileus (blocked intestine).
- are taking warfarin or similar medicines, used to thin the blood.
- have been told you have enzymes that do not work well (such as “CYP2D6 poor metabolizer” or “CYP2C19 poor metabolizer”).
- had a recent bone fracture or were told you have osteoporosis or risk factors for osteoporosis.
- are lactose intolerant or have one of the following rare hereditary diseases:
 - Galactose intolerance
 - Lapp lactase deficiency
 - Glucose-galactose malabsorption
 Because lactose is a non-medicinal ingredient in NORTRIPTYLINE.

Other warnings you should know about:

Withdrawal symptoms: Do NOT stop taking NORTRIPTYLINE without talking to your healthcare professional first. You may need to lower your dose gradually and careful monitoring by your healthcare professional is required. Stopping NORTRIPTYLINE suddenly may cause withdrawal symptoms including flu-like symptoms, dizziness, nausea, headache, malaise (general discomfort), agitation and stomach cramps.

Driving and using machines: NORTRIPTYLINE can cause you to feel drowsy, dizzy, and confused. Do not drive or operate machinery until you know how NORTRIPTYLINE affects you.

Pregnancy: NORTRIPTYLINE can cross the placenta barrier. It is not known if this is safe for your unborn baby. You should not take NORTRIPTYLINE if you are pregnant unless you and your healthcare professional have discussed the risks and decided that you should. Tell your healthcare professional **right away** if you become pregnant while taking NORTRIPTYLINE.

Breastfeeding: NORTRIPTYLINE is released into breast milk. It is not known if this is safe for your baby. You should not take NORTRIPTYLINE if you are pregnant unless you and your healthcare professional have discussed the risks and decided that you should.

Serotonin toxicity (also known as Serotonin Syndrome): NORTRIPTYLINE can cause serotonin toxicity, a rare but potentially life-threatening condition. It can cause serious changes in how your brain, muscles and digestive system work. You may develop serotonin toxicity if you take NORTRIPTYLINE with certain anti-depressants or migraine medications. Serotonin toxicity symptoms include:

- fever, sweating, shivering, diarrhea, nausea, vomiting;
- muscle shakes, jerks, twitches or stiffness, overactive reflexes, loss of coordination
- fast heartbeat, changes in blood pressure;

- confusion, agitation, restlessness, hallucinations, mood changes, unconsciousness, and coma.

Angle-Closure Glaucoma: NORTRIPTYLINE can cause angle-closure glaucoma (sudden eye pain). Having your eyes examined before you take NORTRIPTYLINE could help identify if you are at risk of having angle-closure glaucoma. Seek immediate medical attention if you experience:

- eye pain;
- changes in vision;
- swelling or redness in or around the eye.

Brugada syndrome (serious heart problem): NORTRIPTYLINE may reveal a hidden heart problem you did not know you had, a problem called Brugada syndrome. Brugada syndrome can be serious and cause sudden death. Get immediate medical help if you experience fainting, dizziness, heart palpitations or abnormal heartbeat during your treatment.

Before you start taking NORTRIPTYLINE, tell your healthcare professional if you:

- have Brugada syndrome.
- have unexplained fainting, or a family history of Brugada syndrome or unexplained sudden death before 45 years of age. This could mean you may have Brugada syndrome.

Surgery: If you have a planned surgery, talk to your healthcare professional as soon as possible. They may ask you to stop taking NORTRIPTYLINE.

Check-ups and testing: Your healthcare professional may do tests to monitor your health while you are taking NORTRIPTYLINE. This may include tests to monitor your blood pressure and check for problems with your heart.

Bone Fracture: Taking NORTRIPTYLINE may increase your risk of breaking a bone if you are elderly, have osteoporosis, or have other major risk factors for breaking a bone. You should take extra care to avoid falls, especially if you get dizzy or have low blood pressure.

Cavities: Long term use of NORTRIPTYLINE can cause dental cavities.

Serious skin reactions: Cases of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), which can be serious or life-threatening, have been reported with NORTRIPTYLINE. Get immediate medical help if you experience:

- fever
- severe rash
- peeling skin
- swelling of the face
- swollen lymph glands
- flu-like feeling
- yellow skin or eyes
- shortness of breath
- swelling of the legs
- dry cough

- chest pain or discomfort
- feeling thirsty
- urinating less often, less urine or dark urine

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

Serious Drug Interactions

Do **not** take NORTRIPTYLINE if you are taking a monoamine oxidase inhibitor (MAOI), or if you have taken one in the last 14 days as this can cause serious side effects.

The following may also interact with NORTRIPTYLINE:

- cimetidine, used to treat stomach ulcers
- anticholinergic medications such as certain medicines used to treat asthma, chronic obstructive pulmonary disease, stomach and gut problems, and Parkinson’s disease
- medicines called sympathomimetics such as adrenaline, ephedrine, isoprenaline, noradrenaline, phenylephrine and phenylpropanolamine
- dextromethorphan used to treat cough
- other antidepressants such as tricyclic antidepressants, selective serotonin reuptake inhibitors (SSRIs) like fluoxetine, and serotonin and norepinephrine reuptake inhibitors (SNRIs)
- medicines used to treat mental and emotional problems called phenothiazines, such as chlorpromazine, thioridazine, trifluoperazine
- medicines used to treat seizures such as carbamazepine and valproic acid
- medicines used to treat irregular heartbeats such as propafenone, flecainide, encainide and quinidine
- medicines used to treat thyroid problems such as levothyroxine
- medicines used to treat high blood pressure such as guanethidine, reserpine, debrisoquine, betanidine, methyldopa, and clonidine
- medicines used to treat pain called opioids, such as tramadol and fentanyl
- lithium, used to treat bipolar disorder
- buspirone, used to treat generalized anxiety disorder
- medicines called triptans, used to treat migraines or headaches
- alcohol
- herbal medicines such as goldenseal, garcinia cambogia, ashwagandha, and St. John's wort
- medicines used to treat schizophrenia and other mental health problems, such as pimozide, sertindole*, fluphenazine, thioridazine* and haloperidol.
- medicines used to treat bacterial infections such as erythromycin, clarithromycin, tacrolimus, rifampicin* and ciprofloxacin.
- medicines used to treat malaria such as quinine, halofantrine* and chloroquine.

- medicines used to treat fungal infections such as ketoconazole, itraconazole, fluconazole and terbinafine.
- domperidone used to treat nausea and vomiting and increase milk supply in breastfeeding mothers.
- medicines used to treat nausea and vomiting in cancer patients such as ondansetron.
- medicines used to treat cancer such as sunitinib and vorinostat.
- medicines used to treat breathing problems like asthma and COPD such as salmeterol.
- warfarin or similar medicines, used to thin the blood.
- baclofen, used to treat muscle spasms.
- nitrates, used to treat angina (chest pain).
- oral contraceptives, used to prevent pregnancy.

* Product is not or no longer marketed in Canada.

How to take NORTRIPTYLINE:

- Always take NORTRIPTYLINE exactly as your healthcare professional has told you. Check with your healthcare professional if you are not sure.
- You should continue to take your medicine even if you do not feel better. It may take a number of weeks for your medicine to start working.
- Do not stop taking or change your dose without talking to your healthcare professional. If you are stopping this medication you may need to lower the dose gradually. Stopping NORTRIPTYLINE suddenly can cause withdrawal symptoms.

Usual dose:

Your healthcare professional will determine the dose that is right for you. Take NORTRIPTYLINE exactly as directed. Based on how you respond to NORTRIPTYLINE and your tolerability, your healthcare professional may change your dose. If you are elderly or have other health problems such as problems with your liver, your healthcare professional may prescribe a lower dose.

Overdose:

Signs of overdose may include blurred vision, confusion, restlessness, changes in body temperature, agitation, vomiting, uncontrolled movements, dilated pupils, fever, rapid heartbeats, constipation, dry mouth, difficulties passing water, fits, difficulty breathing, renal failure, repetitive, uncontrolled eye movements, impaired coordination, slurred speech, involuntary twitching or writhing movements, coma, low blood pressure, and abnormal heart rhythms

If you think you, or a person you are caring for, have taken too much NORTRIPTYLINE, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed Dose:

If you forget to take NORTRIPTYLINE, skip the missed dose and take the next dose as scheduled.

What are possible side effects from using NORTRIPTYLINE?

These are not all the possible side effects you may have when taking NORTRIPTYLINE. If you experience any side effects not listed here, tell your healthcare professional.

The side effects may include:

- restlessness
- constipation
- nausea and vomiting
- decrease appetite
- stomach pain
- diarrhea
- changes in taste
- black tongue
- changes in weight (gain or loss)
- increased sweating
- drowsiness
- dizziness
- weakness
- tiredness
- headache
- hair loss
- trouble sleeping
- fatigue
- itching
- dry mouth, sore mouth

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
UNKNOWN FREQUENCY			
Stomatitis (mouth sores, redness and swelling of the lining of the mouth)	✓		
Digestive system problems: diarrhea, loss of appetite, nausea, stomach pain, unpleasant taste in the mouth, upset stomach, vomiting, black tongue, constipation, heartburn	✓		
Dry mouth, sometimes with a swollen salivary gland		✓	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
(enlargement, pain and redness of salivary glands) or gingivitis (inflammation of gums)			
Urticarial reaction: skin with red spots which burn, itch or sting	✓		
Nocturia (excessive urination at night)		✓	
Feeling weak, dizzy, tired or have a headache, jitteriness	✓		
Insomnia: trouble falling asleep, staying asleep, waking up too early and not being able to get back to sleep	✓		
Mania: elevated or irritable mood, decreased need for sleep, racing thoughts		✓	
Allergic reaction: rash, hives, swelling of the face, lips and tongue or throat, difficulty swallowing or breathing, fever		✓	
Drug reaction with eosinophilia and systemic symptoms (DRESS) (serious skin reaction that may affect more than one organ): fever, severe rash, swollen lymph glands, flu-like feeling, yellow skin or eyes, shortness of breath, dry cough, chest pain or discomfort, urinate less often, less urine			✓
Bone marrow depression: easy bruising, bleeding, nose bleeds, bleeding gums, red spots on the skin, fever and chills, rash, extreme fatigue, pale skin and lips			✓
Nervous system problems: shaking, numbness and tingling of the hands and feet, clumsiness and lack of coordination, loss of balance, uncontrolled twitching or		✓	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
jerking, slurred speech, ringing in the ears, tremors, loss of taste, difficulty to form or pronouncing words			
Hypertension (high blood pressure): shortness of breath, fatigue, dizziness or fainting, chest pain or pressure, swelling in your ankles and legs, bluish colour to your lips and skin, racing pulse or heart palpitations		✓	
Hypotension (low blood pressure): dizziness, fainting, light-headedness, blurred vision, nausea, vomiting, fatigue (may occur when you go from lying or sitting to standing up)		✓	
Increased or decreased blood sugar: frequent urination, thirst, hunger, shakiness, sweating and chills, irritability, confusion, dizziness		✓	
Photosensitivity: Increased sensitivity of the skin to sun		✓	
Reproductive problems: swelling of testicles, impotence in men, increase in breast tissue (in men and women), increased production or outflow of breast milk without breast feeding, change in sex drive		✓	
Heart rhythm problems: palpitations (rapid, pounding, or irregular heartbeat), changes in the rhythm or rate of the heartbeat, abnormal fast heartbeat, dizziness, fainting		✓	
Paralytic ileus (muscles of the intestines do not allow food to		✓	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
pass through causing blocked intestine): stomach bloating, gas, constipation, nausea and vomiting, dehydration			
Difficulty passing urine		✓	
Mental health problems: confusion, hallucinations, excitement, nightmares, problems with attention, anxiety		✓	
Withdrawal symptoms: nausea, headache, irritability, restlessness, dream and sleep disturbance, generally feeling unwell, behavioural changes		✓	
Myocardial infarction (heart attack): pressure or squeezing pain between the shoulder blades, in the chest, jaw, left arm or upper abdomen, shortness of breath, dizziness, fatigue, light-headedness, clammy skin, sweating, indigestion, anxiety, feeling faint and possible irregular heartbeat.			✓
Stroke: Sudden numbness or weakness of your arm, leg or face, especially if only on one side of the body; sudden confusion, difficulty speaking or understanding others; sudden difficulty in walking or loss of balance or coordination; suddenly feeling dizzy or sudden severe headache with no known cause.			✓
Coma: Prolonged state of unconsciousness, unable to respond to stimuli			✓
Seizures (fits): uncontrollable shaking with or without loss of			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
consciousness			
Lupus-like syndrome (migratory arthritis): Pain moves from one joint to another, positive Antinuclear antibody test and positive rheumatoid factor		✓	
SIADH—syndrome of inappropriate antidiuretic hormone secretion: concentrated urine (dark in colour), feel or are sick, have muscle cramps, confusion and fits (seizures) which may be due to inappropriate secretion of ADH (antidiuretic hormone).			✓
Aplastic anemia (when cells meant to develop into mature blood cells are damaged): fatigue, weakness, pale skin		✓	
Eosinophilia (increased numbers of certain white blood cells): abdominal pain, rash, weight loss, wheezing		✓	
Agranulocytosis (decrease in white blood cells): frequent infection with fever, chills, sore throat		✓	
Thrombocytopenia (low blood platelets): bruising or bleeding for longer than usual if you hurt yourself, fatigue and weakness		✓	
Leukopenia (decreased white blood cells): infections, fatigue, fever, aches, pains and flu-like symptoms		✓	
Hyponatremia (low level of sodium in your blood): loss of energy, tiredness, muscle weakness or cramps, seizures		✓	

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
Jaundice (build-up of bilirubin in the blood): yellowing of the skin and eyes, dark urine, light-colored stool, itching all over your body		✓	
Hepatitis (inflammation of the liver): Abdominal pain, fatigue, fever, itchiness, light-colored stool, trouble thinking clearly, yellowing of the skin			✓
Hepatic necrosis (death of liver cells): abdominal pain and dark urine, fever, light-colored stool, and jaundice (a yellow appearance of the skin and white portion of the eyes)			✓
Angle-Closure Glaucoma: increased pressure in the eye, pupil dilation, blurred vision, eye pain and swelling or redness in or around the eye		✓	
New or worsened emotional or behavioural problems: feeling very agitated or restless, acting aggressive, being angry or violent, acting on dangerous impulses, thoughts of harming others, thoughts of suicide or dying attempts to commit suicide			✓
Serotonin toxicity (also known as serotonin syndrome): a reaction which may cause feelings of agitation or restlessness, flushing, muscle twitching, involuntary eye movements, heavy sweating, high body temperature (above 38°C), or rigid muscles			✓
QT interval prolongation and Brugada syndrome (serious and potentially life threatening)			✓

Serious side effects and what to do about them			
Symptom / effect	Talk to your healthcare professional		Stop taking drug and get immediate medical help
	Only if severe	In all cases	
electrical problems with the heart): dizziness, fainting, fast heartbeat, palpitations, abnormal heart rate, seizures (fits)			

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting Side Effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (<https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html>) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

- Store at room temperature (15°C - 30°C). Keep in a tightly closed container.
- Medicines should not be disposed of via wastewater or household waste. Your healthcare professional will throw away any medicines that are no longer being used. These measures will help protect the environment.
- Keep out of reach and sight of children.

If you want more information about NORTRIPTYLINE:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the Health Canada website: (<https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/drug-product-database.html>); the manufacturer's website (<http://www.apotex.ca/products>), or by calling 1-800-667-4708.

This leaflet was prepared by Apotex Inc. Toronto, Ontario, Canada M9L 1T9.

Last Revised: NOV 29, 2024